Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
NCT05062837
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
UNKNOWN
Status
62
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Hepatectomy Combined With Camrelizumab and Apatinib
Sponsor
Guangxi Medical University
Collaborators
[object Object]